Literature DB >> 24663495

Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy.

Mariacristina Siotto1, Patrizio Pasqualetti, Massimo Marano, Rosanna Squitti.   

Abstract

Ceruloplasmin (Cp) is a serum ferroxidase that plays an essential role in iron metabolism. It is routinely tested by immunoturbidimetric assays that quantify the concentration of the protein both in its active and inactive forms. Cp activity is generally analyzed manually; the process is time-consuming, has a limited repeatability, and is not suitable for a clinical setting. To overcome these inconveniences, we have set the automation of the o-dianisidine Cp activity assay on a Cobas Mira Plus apparatus. The automation was rapid and repeatable, and the data were provided in terms of IU/L. The assay was adapted for human sera and showed a good precision [coefficient of variation (CV) 3.7 %] and low limit of detection (LoD 11.58 IU/L). The simultaneous analysis of Cp concentration and activity in the same run allowed us to calculate the Cp-specific activity that provides a better index of the overall Cp status. To test the usefulness of this automation, we tested this assay on 104 healthy volunteers and 36 patients with Wilson's disease, hepatic encephalopathy, and chronic liver disease. Cp activity and specific activity distinguished better patients between groups with respect to Cp concentration alone, and providing support for the clinical investigation of neurological diseases in which liver failure is one of the clinical hallmarks.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24663495     DOI: 10.1007/s00702-014-1196-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  Limit of blank, limit of detection and limit of quantitation.

Authors:  David A Armbruster; Terry Pry
Journal:  Clin Biochem Rev       Date:  2008-08

2.  Automated assay of ceruloplasmin by kinetic analysis of o-dianisidine oxidation.

Authors:  J D Boyett; H P Lehmann; M F Beeler
Journal:  Clin Chim Acta       Date:  1976-06-01       Impact factor: 3.786

3.  Standardization of serum ceruloplasmin concentrations in international enzyme units with o-dianisidine dihydrochloride as substrate.

Authors:  H P Lehmann; K H Schosinsky; M F Beeler
Journal:  Clin Chem       Date:  1974-12       Impact factor: 8.327

4.  Mobilization of liver iron by ferroxidase (ceruloplasmin).

Authors:  S Osaki; D A Johnson
Journal:  J Biol Chem       Date:  1969-10-25       Impact factor: 5.157

5.  Measurement of blood holoceruloplasmin by EIA using a mouse monoclonal antibody directed to holoceruloplasmin. Implication for mass screening of Wilson disease.

Authors:  F Endo; K Taketa; K Nakamura; H Awata; A Tanoue; Y Eda; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Early diagnosis of Wilson's disease.

Authors:  S Hiyamuta; K Shimizu; T Aoki
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

7.  [The antioxidant system of transferrin-ceruloplasmin in experimental hypercholesterolemia].

Authors:  A V Kozlov; V I Sergienko; Iu A Vladimirov; O A Azizova
Journal:  Biull Eksp Biol Med       Date:  1984-12

8.  Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride.

Authors:  K H Schosinsky; H P Lehmann; M F Beeler
Journal:  Clin Chem       Date:  1974-12       Impact factor: 8.327

9.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Ceruloplasmin/Transferrin system is related to clinical status in acute stroke.

Authors:  Claudia Altamura; Rosanna Squitti; Patrizio Pasqualetti; Chiara Gaudino; Paola Palazzo; Francesco Tibuzzi; Domenico Lupoi; Maurizio Cortesi; Paolo Maria Rossini; Fabrizio Vernieri
Journal:  Stroke       Date:  2009-02-19       Impact factor: 7.914

View more
  10 in total

1.  An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain.

Authors:  Mariacristina Siotto; Irene Aprile; Ilaria Simonelli; Costanza Pazzaglia; Mariacarla Ventriglia; Massimo Santoro; Isabella Imbimbo; Rosanna Squitti; Luca Padua
Journal:  J Neural Transm (Vienna)       Date:  2017-10-30       Impact factor: 3.575

Review 2.  New tools for Wilson's disease diagnosis: exchangeable copper fraction.

Authors:  France Woimant; Nouzha Djebrani-Oussedik; Aurélia Poujois
Journal:  Ann Transl Med       Date:  2019-04

3.  Chloride Control of the Mechanism of Human Serum Ceruloplasmin (Cp) Catalysis.

Authors:  Shiliang Tian; Stephen M Jones; Anex Jose; Edward I Solomon
Journal:  J Am Chem Soc       Date:  2019-06-27       Impact factor: 15.419

4.  Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy.

Authors:  Massimo Marano; Umberto Vespasiani Gentilucci; Claudia Altamura; Mariacristina Siotto; Rosanna Squitti; Serena Bucossi; Livia Quintiliani; Simone Migliore; Federico Greco; Laura Scarciolla; Carlo Cosimo Quattrocchi; Antonio Picardi; Fabrizio Vernieri
Journal:  Metab Brain Dis       Date:  2015-08-27       Impact factor: 3.584

5.  Biomarkers for diagnosis of Wilson's disease.

Authors:  Aidan Ryan; Sarah J Nevitt; Orla Tuohy; Paul Cook
Journal:  Cochrane Database Syst Rev       Date:  2019-11-19

6.  Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.

Authors:  Guillaume Grolez; Caroline Moreau; Bernard Sablonnière; Guillaume Garçon; Jean-Christophe Devedjian; Sayah Meguig; Patrick Gelé; Christine Delmaire; Regis Bordet; Luc Defebvre; Ioav Z Cabantchik; David Devos
Journal:  BMC Neurol       Date:  2015-05-06       Impact factor: 2.474

7.  Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase.

Authors:  Da-Wu Zeng; Jing Dong; Jia-Ji Jiang; Yue-Yong Zhu; Yu-Rui Liu
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

8.  Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study.

Authors:  Rosanna Squitti; Mariacristina Siotto; Giovanni Assenza; Nadia M Giannantoni; Mauro Rongioletti; Filippo Zappasodi; Franca Tecchio
Journal:  Front Neurol       Date:  2018-05-30       Impact factor: 4.003

9.  The Use of Biochemical Measurements to Identify Pre-Slaughter Stress in Pasture Finished Beef Cattle.

Authors:  Kate M W Loudon; Garth Tarr; David W Pethick; Ian J Lean; Rod Polkinghorne; Maddison Mason; Frank R Dunshea; Graham E Gardner; Peter McGilchrist
Journal:  Animals (Basel)       Date:  2019-07-31       Impact factor: 2.752

10.  Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants.

Authors:  Rosanna Squitti; Mariacarla Ventriglia; Ilaria Simonelli; Cristian Bonvicini; Alfredo Costa; Giulia Perini; Giuliano Binetti; Luisa Benussi; Roberta Ghidoni; Giacomo Koch; Barbara Borroni; Alberto Albanese; Stefano L Sensi; Mauro Rongioletti
Journal:  Biomolecules       Date:  2021-06-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.